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The mannose 6-phosphate-binding sites of M6P/IGF2R determine its
capacity to suppress matrix invasion by squamous cell carcinoma cells
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Lukas MACH1
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The M6P (mannose 6-phosphate)/IGF2R (insulin-like growth
factor II receptor) interacts with a variety of factors that impinge
on tumour invasion and metastasis. It has been shown that
expression of wild-type M6P/IGF2R reduces the tumorigenic and
invasive properties of receptor-deficient SCC-VII squamous cell
carcinoma cells. We have now used mutant forms of M6P/IGF2R
to assess the relevance of the different ligand-binding sites of the
receptor for its biological activities in this cellular system. The
results of the present study demonstrate that M6P/IGF2R does
not require a functional binding site for insulin-like growth factor
II for inhibition of anchorage-independent growth and matrix
invasion by SCC-VII cells. In contrast, the simultaneous mutation
of both M6P-binding sites is sufficient to impair all cellular
functions of the receptor tested. These findings highlight that
the interaction between M6P/IGF2R and M6P-modified ligands
is not only important for intracellular accumulation of lysosomal
enzymes and formation of dense lysosomes, but is also crucial
for the ability of the receptor to suppress SCC-VII growth and
invasion. The present study also shows that some of the biological
activities of M6P/IGF2R in SCC-VII cells strongly depend on
a functional M6P-binding site within domain 3, thus providing
further evidence for the non-redundant cellular functions of the
individual carbohydrate-binding domains of the receptor.
Key words: cell migration, extracellular matrix, insulin-like
growth factor (IGF), lysosome, mannose 6-phosphate (M6P),
proteolysis.
INTRODUCTION
Intracellular trafficking of most soluble lysosomal proteins
depends on their interaction with M6P (mannose 6-phosphate)
receptors [1]. Two M6P receptors are known to occur in mam-
malian cells, the 300 kDa M6P/IGF2R [IGF (insulin-like growth
factor) II receptor] and MPR46 (46 kDa M6P receptor). Studies
on MPR46- and/or M6P/IGF2R-negative cells have indicated that
the simultaneous presence of both receptors is necessary for the
optimal delivery of lysosomal enzymes to these compartments
[2,3]. However, M6P/IGF2R is generally more efficient than
MPR46 in mediating lysosomal enzyme transport, which is at
least partly owing to the capacity of M6P/IGF2R to retrieve
secreted M6P-modified proteins via the endocytic route [4].
M6P/IGF2R is a multifunctional membrane-associated protein
with a repetitive structure consisting of 15 contiguous repeating
segments [5]. Its two M6P-binding sites are located in domains 3
and 9. An additional binding site for M6P-N-acetylglucosamine
residues is located in domain 5 of the protein [6]. Aside of
lysosomal enzymes, M6P/IGF2R is supposed to bind also other
glycoproteins, such as latent TGF-β (transforming growth factor
β) in an M6P-dependent manner. It has been suggested that
binding to M6P/IGF2R is required for the pericellular activation
of TGF-β [7]. However, the physiological significance of the
interaction of M6P/IGF2R with non-lysosomal M6P-modified
proteins is still largely unclear.
In addition to interactions mediated by its carbohydrate-binding
sites, M6P/IGF2R also has the capacity to bind various proteins by
other modes of action, including IGF-II. The principal binding site
for IGF-II resides in domain 11 of the receptor [8,9]. It has been
shown that mice with a targeted disruption of the M6P/IGF2R
locus die perinatally, which can be rescued by simultaneous
ablation of the IGF-II gene [10]. This indicates that M6P/IGF2R
plays a pivotal role in the control of the biological activities of
IGF-II. Substantial evidence has been provided that M6P/IGF2R
promotes endocytosis and subsequent degradation of IGF-II in
lysosomes, thus restricting its bioavailability. Hence M6P/IGF2R
counteracts excessive IGF-II signalling through type 1 IGF and
insulin receptors rather than directly participating in a signal
transduction cascade [11]. It has, however, been proposed that
M6P/IGF2R is also capable of acting as a signalling receptor
under certain circumstances [12,13].
Given the physiological significance of M6P/IGF2R in the
control of important signal transduction events, it is of note that
the gene encoding the receptor is frequently mutated in human
and animal tumours [14,15]. Evidence has been provided that
loss-of-function mutations in M6P/IGF2R contribute to cancer
progression, lending support to the notion that this receptor
might be a tumour suppressor. Tumour-associated M6P/IGF2R
alterations were mainly located in domains 9, 10 and 11 of
the receptor [16–19], with this region of the protein hosting
one of the two M6P-binding sites and the major site of
interaction with IGF-II [5]. The tumour-suppressive potential
of M6P/IGF2R is supposed to rely largely on its dampening
impact on IGF-II signalling. It has also been suggested that
M6P/IGF2R restricts tumour progression by modulation of latent
TGF-β activation at the cell surface [20]. However, M6P/IGF2R
binds a variety of other factors that could exert an influence on
the proliferation, migration and/or invasiveness of tumour cells,
including heparanase and cysteine cathepsins [21–23].
Abbreviations used: CD, cathepsin D; CL, cathepsin L; GM130, cis-Golgi matrix protein of 130 kDa; HEX, β-N-acetylhexosaminidase; IGF, insulin-like
growth factor; IGF2R, IGF-II receptor; M6P, mannose 6-phosphate; MPR46, 46 kDa M6P receptor; PDI, protein disulfide isomerase; SCC, squamous cell
carcinoma; TGF-β, transforming growth factor β; wt, wild-type.
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Although the growth-suppressive role of M6P/IGF2R is well
documented, its impact on tumour invasion and metastasis
remains poorly understood. It has been put forward that loss
of M6P/IGF2R may promote the invasiveness of malignant
tumour cells [24]. Various studies have shown that M6P/IGF2R
indeed has the capacity to impede tumour cell migration
[25,26]. Interestingly, we have recently found that M6P/IGF2R
modulates the invasiveness of liver cells via its capacity to bind
M6P-modified proteins [27]. However, the exact mechanisms
underlying the anti-invasive properties of M6P/IGF2R in SCC
(squamous cell carcinoma) cells remain to be elucidated.
Furthermore, it is still unknown whether the individual M6P-
binding sites of the receptor serve complementary or redundant
functions in the context of anchorage-independent growth and
matrix invasion by cancer cells.
We have previously reported that reconstitution of M6P/IGF2R
expression in receptor-deficient SCC-VII cells improves the intra-
cellular accumulation of lysosomal enzymes, restores the
formation of dense lysosomes and reduces the invasive propensity
of the cells [25]. This cellular system was now used to assess the
relevance of the different ligand-binding sites of M6P/IGF2R
for the biological activities of the receptor by introducing
point mutations known to selectively interfere with binding of
individual ligands [28,29].
MATERIALS AND METHODS
Antibodies
Rabbit antisera raised against bovine M6P/IGF2R, mouse CD
(cathepsin D) and mouse proCL (cathepsin L) were kindly
provided by Professor Bernard Hoflack (Technical University
of Dresden, Dresden, Germany), Professor Regina Pohlmann
(University of Mu¨nster, Mu¨nster, Germany) and Professor Ann
H. Erickson (University of North Carolina, Chapel Hill, U.S.A.)
respectively. Monoclonal antibodies against rat GM130 (cis-Golgi
matrix protein of 130 kDa; BD Biosciences) and PDI (protein
disulfide isomerase; Stressgen Bioreagents) were obtained from
the indicated commercial suppliers.
Generation of SCC-VII cells expressing human M6P/IGF2R variants
The generation of mutant M6P/IGF2R cDNAs and their insertion
into the expression vector pAHygCMV2 has been described
previously [27]. The plasmid pAHygCMV2/IGF2R encoding
wt (wild-type) human M6P/IGF2R was as described previously
[25]. M6P/IGF2R-deficient parental SCC-VII cells [30] were
transfected with wt or mutant pAHygCMV2/IGF2R constructs
using Lipofectin® (Invitrogen) and then subjected to selection
with hygromycin B (Invitrogen). The clones thus obtained were
tested for M6P/IGF2R expression as outlined previously for the
isolation of SCC-VII/IGF2R wt-1 and wt-2 cells expressing
the wt receptor [25,31]. The isolation of mock-transfected SCC-
VII cells has been reported previously [25,30].
Preparation of total cellular membranes
Confluent cell monolayers (1×107 cells) were harvested in 500 μl
of PBS containing proteinase inhibitors {1 mM PMSF, 5 μg/ml
E-64 [trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane]
and 5 μg/ml leupeptin} and disrupted by ultrasonication. Post-
nuclear supernatants were obtained by low-speed centrifugation
(5 min at 320 g, followed by 5 min at 800 g) and then centrifuged
for 60 min at 35000 rev./min (Beckman Coulter 50 Ti rotor) to
sediment the membranes.
Phosphomannan-binding assays
Total cellular membranes were resuspended in 100 μl of binding
buffer [0.15 M NaCl, 50 mM imidazole/HCl (pH 7.0) and 0.02%
NaN3] containing proteinase inhibitors and extracted with 1%
(w/v) Triton X-100 for 30 min at 0 ◦C. Aliquots of these membrane
extracts corresponding to 150 μg of total protein were diluted
10-fold with binding buffer and incubated with 40 μl of settled
phosphomannan–Sepharose beads [25] on an end-over-end mixer
for 16 h at 4 ◦C. The beads were then washed five times with 1 ml
of binding buffer containing 0.1% Triton X-100. After another
wash with 40 μl of 5 mM glucose 6-phosphate (Sigma–Aldrich),
the specifically bound material was eluted with 40 μl of 5 mM
M6P (Sigma–Aldrich) in the binding buffer.
IGF-II-binding assays
Total cellular membrane extracts (100 μg of total protein)
were diluted 10-fold with binding buffer [0.4 M KCl, 50 mM
imidazole/HCl (pH 7.0) and 0.02% NaN3 containing 0.1%
Triton X-100]. The samples were then incubated either with 1 μg
of biotinylated IGF-II (Gropep) or BSA for 16 h at 4 ◦C on an end-
over-end mixer, prior to capture of the biotinylated proteins with
40 μl of avidin–Sepharose beads for another 16 h at 4 ◦C [25]. The
beads were then washed five times with 1 ml of binding buffer
and twice with 1 ml of 10 mM Tris/HCl (pH 6.8). Finally, bound
proteins were eluted with SDS/PAGE sample buffer [125 mM
Tris/HCl (pH 6.8), 10 mM dithioerythritol, 1% (w/v) SDS, 10%
(w/v) glycerol and 0.01% Bromophenol Blue] by incubation for
5 min at 65 ◦C.
Immunoblotting analysis
Western blotting analysis of M6P/IGF2R was performed after
separation by SDS/PAGE (7.5% gel) under reducing conditions.
SDS/PAGE (14% gel) was used for the analysis of the
other proteins. Samples were denatured for 5 min at 65 ◦C
(M6P/IGF2R) or 95 ◦C (other proteins) prior to electrophoresis
and blotting on to Hybond-C nitrocellulose membranes (GE
Healthcare). Bound primary antibodies were detected with goat
anti-rabbit or goat anti-mouse immunoglobulins conjugated
to horseradish peroxidase (Jackson ImmunoResearch) and
chemiluminescence reagents [30]. Densitometric analysis of
immunoblots was done using ImageQuaNT v4.2 software
(Molecular Dynamics).
Subcellular fractionation
Post-nuclear supernatants were obtained and fractionated
by density-gradient centrifugation in 18% (v/v) Percoll
(GE Healthcare) gradients (initial density of 1.055 g/ml) as
described previously [32]. The gradients were divided into ten
fractions which were then analysed for their activity of the
lysosomal marker enzyme HEX (β-N-acetylhexosaminidase). For
immunoblot detection of other lysosomal proteins (CD and CL)
as well as GM130 (Golgi) and PDI (endoplasmic reticulum),
fractions 1–3 (heavy fraction), 4–7 (intermediate fraction) and
8–10 (light fraction) were pooled and extracted as described
previously [25,31].
Proliferation assays
Cells (6×105) were resuspended in 10 ml of culture medium
and seeded into 58-cm2 dishes. After incubation for 24–72 h, the
cultures were harvested by trypsinization and their cell number
determined using a Fuchs–Rosenthal chamber.
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Soft agar colony-formation assays
Cells (3×103) were added to 4 ml of medium containing 0.3%
agar and seeded into 21-cm2 dishes. Colonies obtained after
culture for 3 weeks were then counted and their areas determined
as described previously [25].
Matrigel invasion assays
Cells (5×104) were resuspended in 200 μl of serum-free medium
containing 0.1% BSA and then seeded on top of Matrigel-coated
filters placed in wells filled with 700 μl of conditioned fibroblast
medium [25]. After incubation for 24 h at 37 ◦C, the cells were
fixed with methanol and then stained with Crystal Violet. After
removal of the cells remaining on the upper side of the filter with
a cotton swab, the filters were analysed as described previously
[25].
Other methods
Lysosomal enzyme secretion studies and fluorescence microscopy
were performed as described previously [25,31,33]. Total protein
content was determined either with the Bio-Rad Protein Assay kit
(Bio-Rad Laboratories) or the BCA (bicinchoninic acid) Protein
Assay Kit (Pierce) as appropriate, using BSA as a standard.
Statistical analyses were performed using Student’s t test, with
P < 0.05 being considered significant.
RESULTS
Characterization of mutant M6P/IGF2R variants stably expressed in
SCC-VII cells
M6P/IGF2R contains three carbohydrate-binding sites within
its extracytoplasmic region, with two of them displaying high
affinities for M6P [5]. Studies on bovine M6P/IGF2R have
demonstrated an important role for conserved arginine residues
in domain 3 (Arg435) and domain 9 (Arg1334) in M6P binding.
Replacement of Arg435 and Arg1334 (pre-protein numbering)
with alanine or charge-conservative lysine residues resulted
in complete loss of M6P-binding activity [34]. A structure-
based sequence alignment identified Arg426 (domain 3) and
Arg1325 (domain 9) as the corresponding residues in the human
receptor [18]. We therefore prepared a Lys426/Lys1325 double-
mutant human M6P/IGF2R construct (M6P/IGF2R Dom3/9mut)
as well as the respective single-mutant receptor cDNAs, each
of the latter still harbouring one functional M6P-binding site.
Furthermore, a cDNA variant encoding a point mutation in domain
11 (Ile1572→Thr) was generated (M6P/IGF2R Dom11mut). This
mutation has been previously shown to abrogate binding of IGF-
II [8,9].
The mutant M6P/IGF2R cDNAs were then stably expressed
in M6P/IGF2R-deficient SCC-VII cells. For each mutant, at
least two representative transfectants were chosen for further
experiments. The expression levels of the different M6P/IGF2R
constructs in the selected cell lines were estimated by immuno-
blotting (Supplementary Table S1 at http://www.biochemj.org/
bj/451/bj4510091add.htm). The receptor content of all selected
lines (1.0–2.2 pmol/mg) was well within the physiological range
[35] and comparable with that of SCC-VII cells expressing wt
M6P/IGF2R (1.0–4.1 pmol/mg) [25].
The subcellular distribution of the mutant M6P/IGF2R variants
was investigated by means of fluorescence microscopy. We have
previously shown that wt M6P/IGF2R ectopically expressed in
SCC-VII cells is present in the perinuclear compartments remin-
iscent of the Golgi apparatus and Golgi-associated structures such
as the trans-Golgi network [25]. Immunocytochemical detection
of all mutant receptor forms revealed a similar subcellular
distribution. This could be verified by complete colocalization
with the Golgi marker GM130 (Supplementary Figure S1 at http://
www.biochemj.org/bj/451/bj4510091add.htm).
To investigate whether the mutant M6P/IGF2R forms stably
expressed in SCC-VII cells fold and function properly, M6P- and
IGF-II-binding studies with membrane extracts of the respective
cell lines were performed. The M6P/IGF2R Dom3mut and
Dom9mut constructs containing single Arg→Lys point mutations
were found to bind IGF-II and phosphomannan, an M6P-
containing polysaccharide, like the wt receptor. As anticipated,
the double mutant M6P/IGF2R Dom3/9mut did not interact
with phosphomannan, but retained its ability to bind IGF-II.
Conversely M6P/IGF2R Dom11mut was found to be incapable of
interacting with IGF-II, whereas its binding to phosphomannan
was not compromized (Figure 1).
Lysosomal enzyme transport in SCC-VII cells expressing mutant
M6P/IGF2R variants
In order to assess whether the M6P/IGF2R mutants are functional
in lysosomal enzyme trafficking, the intra- and extra-cellular
activities of the lysosomal marker HEX were determined. It
should be noted that this assay does not discriminate between
direct lysosomal sorting of HEX and reinternalization of secreted
enzyme. In our previous study [25], we have already reported that
expression of the wt M6P/IGF2R in SCC-VII cells results in a
markedly reduced HEX content of the medium (11–24% of the
total activity) as compared with parental and mock-transfected
cells (59–62%). A similar observation was now made for
M6P/IGF2R Dom11mut-producing cells (16–21% extracellular
HEX), indicating that M6P/IGF2R Dom11mut is fully competent
in delivering lysosomal enzymes to their intracellular destination
(Table 1).
Interestingly, extracellular accumulation of HEX by SCC-VII
cells expressing M6P/IGF2R Dom3mut (23–31%) or Dom9mut
(20–24%) is at best moderately increased. Expression of
M6P/IGF2R Dom3/9mut led to more HEX being present in the
medium (33–43%). However, this value is still significantly
lower than that determined for mock-transfected or parental SCC-
VII cells (Table 1). To assess whether the improved retention
of HEX by SCC-VII cells expressing mutant M6P/IGF2R is
indeed related to the ectopic presence of the receptor, the cells
were treated with NH4Cl, a lysosomotropic amine known to
interfere with intracellular sorting of lysosomal enzymes. As
previously reported for the wt receptor [25], NH4Cl treatment
of cells expressing M6P/IGF2R mutants increased the fraction of
extracellular HEX to 45–64% (Supplementary Table S2 at
http://www.biochemj.org/bj/451/bj4510091add.htm).
We also analysed the intracellular retention of two other
lysosomal enzymes, CD and CL, by SCC-VII cells expressing
M6P/IGF2R variants with impaired M6P-binding sites. Upon
expression of wt M6P/IGF2R, the fraction of CD accumulating
in the medium was reduced from 53–67% to 12–15%.
The extracellular CD fraction was also lower in SCC-VII
cells expressing either M6P/IGF2R mutant with only one
functional M6P-binding site (16–43%). In contrast, SCC-
VII cells expressing M6P/IGF2R Dom3/9mut accumulated only
slightly less CD (48–52%) in the medium than parental and
mock-transfected SCC-VII cells (Table 1).
The effect of wt M6P/IGF2R expression on CL retention by
SCC-VII cells is much weaker than for HEX and CD [25],
which could be related to the existence of an alternative targeting
pathway for this enzyme [36]. M6P/IGF2R Dom3mut transfectants
were found to deliver even slightly less CL into their medium
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Figure 1 Ligand-binding properties of mutant forms of M6P/IGF2R
Left-hand panel, membrane extracts of SCC-VII cells expressing either wt or mutant M6P/IGF2R were incubated with either biotinylated IGF-II or BSA prior to the addition of avidin–Sepharose
beads. The bound material was then subjected to immunoblotting analysis with anti-M6P/IGF2R antibodies. Right-hand panel, membrane extracts of SCC-VII cells expressing either wt or mutant
receptor variants were incubated with phosphomannan–Sepharose beads. After washing with glucose 6-phosphate (G6P), the specifically bound proteins were eluted with M6P prior to analysis by
immunoblotting with anti-M6P/IGF2R antibodies. T, total material applied to the beads. *A C-terminally truncated form of M6P/IGF2R [25].
Table 1 Secretion of lysosomal enzymes by parental and transfected SCC-
VII cells
Cells were cultured for 24 h prior to assaying the cell extracts and conditioned medium for their
HEX, CD and CL contents. Results are means +− S.E.M. for 3–17 independent experiments. n.a.,
not analysed.
Cell line Extracellular activity (% of total)
HEX CD CL
SCC-VII/IGF2R wt-1† 11 +− 1* 12 +− 4* 73 +− 4
SCC-VII/IGF2R wt-2 18 +− 3* 15 +− 4* 81 +− 2
SCC-VII/IGF2R Dom3mut-1 31 +− 3* 16 +− 4* 68 +− 7
SCC-VII/IGF2R Dom3mut-2 23 +− 1* 43 +− 1* 74 +− 3
SCC-VII/IGF2R Dom9mut-1 20 +− 2* 27 +− 4* 84 +− 7
SCC-VII/IGF2R Dom3/9mut-1 38 +− 1* 51 +− 12 87 +− 1
SCC-VII/IGF2R Dom3/9mut-2 33 +− 5* 48 +− 2 77 +− 3
SCC-VII/IGF2R Dom3/9mut-3 43 +− 3* 52 +− 7 77 +− 6
SCC-VII/IGF2R Dom11mut-1 21 +− 3* n.a. n.a.
SCC-VII/IGF2R Dom11mut-2 16 +− 3* n.a. n.a.
SCC-VII mock-transfected† 62 +− 2 67 +− 9 85 +− 3
SCC-VII parental† 59 +− 2 53 +− 5 87 +− 2
*P < 0.05, compared with mock-transfected SCC-VII cells.
†HEX data taken from [25].
(68–74%) than cells expressing the wt receptor (73–81%),
whereas M6P/IGF2R Dom9mut (84%) and Dom3/9mut cells (77–
87%) release almost the same proportion of their CL as their
parental and mock-transfected counterparts (85–87%; Table 1).
Despite its presence at the cell surface and its recycling between
the plasma membrane and intracellular compartments, MPR46
fails to mediate internalization of exogenous ligands. In contrast,
M6P/IGF2R is capable of internalizing lysosomal enzymes from
secretions [37]. It has been shown that the addition of M6P to
the culture medium completely inhibits the reuptake of secreted
lysosomal enzymes, without affecting biosynthetic sorting [3]. In
the case of SCC-VII cells expressing wt M6P/IGF2R, cultivation
in the presence of 5 mM M6P increased the extracellular HEX
fraction by 22% of the total enzyme activity. A similar effect was
observed for M6P/IGF2R Dom3mut (21–24%) and Dom9mut cells
(20–22%). In contrast, the effect of M6P on extracellular HEX
accumulation in cultures of M6P/IGF2R Dom3/9mut-expressing
cells was far less pronounced (5%), as also observed for parental
and mock-transfected cells (2%). These results demonstrate
that the presence of either M6P-binding site is sufficient for
normal receptor function in the secretion–recapture pathway
(Figure 2).
M6P/IGF2R-dependent formation of dense lysosomes is impaired
by the simultaneous inactivation of its two M6P-binding sites
To investigate the correlation between the expression of mutant
M6P/IGF2R and the biogenesis of lysosomes in SCC-VII
cells, subcellular fractionation experiments by means of Percoll
density-gradient centrifugation were performed. The dense-
gradient fractions of mock-transfected SCC-VII cells contain
only little HEX activity, as already previously reported for the
parental cell line [24,25,31]. In SCC-VII cells expressing wt
M6P/IGF2R, a much larger HEX fraction (37–45%) was found
to reside in compartments of high buoyant density, mimicking
the sedimentation behaviour of the enzyme in normal cells
[38]. The same was now observed for M6P/IGF2R Dom11mut
cells, with 41% of the total HEX activity detected in the high-
density fractions of the gradient. The subcellular distributions
of CD and CL were also analysed. In SCC-VII cells expressing
the wt receptor, 46–58% of all cellular CD was detected in the
high-density region of the gradient, whereas the accumulation
of CL in dense compartments was less pronounced (27–34%).
Upon expression of M6P/IGF2R Dom11mut, only slightly lower
amounts of CD (33%) and CL (24%) were found in the high-
density gradient fractions. A pronounced accumulation of HEX
(36%), CD (58%) and CL (18%) in dense lysosomes was also
observed for cells expressing M6P/IGF2R Dom9mut. In contrast,
M6P/IGF2R Dom3mut cells were found to store far less of their
HEX (14–21%), CD (5–12%) and CL (11–14%) in high-
density compartments. Even less of the cellular content of HEX
(13–15%), CD (4–7%) and CL (8–13%) was present in the
high-density fractions of M6P/IGF2R Dom3/9mut cells, which
resembles the sedimentation pattern of these enzymes in parental
cells (HEX, 16%; CD, 5%; and CL, 8%). These results show
that the capacity of M6P/IGF2R to mediate the formation of dense
lysosomes in SCC-VII cells strongly depends on the presence of
a functional M6P-binding site within domain 3 (Table 2).
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Figure 2 Lysosomal enzyme delivery via the secretion-recapture pathway in SCC-VII cells expressing mutant M6P/IGF2R
SCC-VII cells expressing either wt or mutant M6P/IGF2R were cultured for 24 h in the presence or absence of 5 mM M6P. Parental and mock-transfected SCC-VII cells were analysed in parallel.
Cell homogenates and conditioned medium were then analysed for their HEX activity. Results are means +− S.E.M. for three to four independent experiments. *P < 0.05, comparison of treated and
untreated cells.
Table 2 Subcellular fractionation of SCC-VII cells expressing mutant forms
of M6P/IGF2R
Post-nuclear supernatants were subjected to Percoll density-gradient centrifugation. Fractions
1–3 (dense), 4–7 (intermediate) and 8–10 (light) were then pooled and assayed for their HEX,
CD and CL contents. Results are means +− S.E.M. for 3–11 independent experiments except for
mock-transfected SCC-VII cells (individual results of two fractionations). Markers for the Golgi
apparatus (GM130) and the endoplasmic reticulum (PDI) were only detected in the light-gradient
fractions.
Activity in dense fractions (% of total)
Cell line HEX CD CL
SCC-VII/IGF2R wt-1† 37 +− 1* 46 +− 4* 27 +− 4*
SCC-VII/IGF2R wt-2 45 +− 3* 58 +− 5* 34 +− 3*
SCC-VII/IGF2R Dom3mut-1 21 +− 1 5 +− 2 11 +− 2
SCC-VII/IGF2R Dom3mut-2 14 +− 3 12 +− 6 14 +− 4
SCC-VII/IGF2R Dom9mut-1 36 +− 5* 58 +− 11* 18 +− 2*
SCC-VII/IGF2R Dom3/9mut-1 15 +− 2 4 +− 3 10 +− 1
SCC-VII/IGF2R Dom3/9mut-2 13 +− 1 5 +− 4 13 +− 1
SCC-VII/IGF2R Dom3/9mut-3 13 +− 1 7 +− 3 8 +− 5
SCC-VII/IGF2R Dom11mut-1 41 +− 5* 33 +− 7* 24 +− 6*
SCC-VII mock-transfected 17, 17 3 8
SCC-VII parental 16 +− 1 5 +− 4 8 +− 2
*P < 0.05, compared with parental SCC-VII cells.
†CD and CL data from [25].
Simultaneous mutation of both M6P-binding sites abolishes the
anti-invasive activity of M6P/IGF2R in SCC-VII cells
Parental SCC-VII cells display an invasive behaviour when
seeded on Matrigel, a reconstituted basement membrane [30].
These invasive properties can be dampened by ectopic expression
of wt M6P/IGF2R [25]. The invasiveness of SCC-VII cells
expressing M6P/IGF2R Dom11mut was 44–56% lower than that
of mock-transfectants, mirroring the effects of wt M6P/IGF2R
expression (48–56% reduction). These data provide strong
evidence that the presence of a functional binding site for IGF-II
is not essential for the anti-invasive capacity of the receptor in
SCC-VII cells (Figure 3).
We have also analysed the impact of mutations within the
M6P-binding sites on the anti-invasive activity of M6P/IGF2R in
SCC-VII cells. As compared with the mock-transfected SCC-VII
cells, the invasiveness of M6P/IGF2R Dom9mut cells is similarly
reduced (by 61%) as that of SCC-VII cells expressing the wt
receptor. M6P/IGF2R Dom3mut expression reduced SCC-VII
invasion to a far lesser extent (4–32%), thus providing further
evidence that the two M6P-binding sites are not functionally
equivalent. Importantly, M6P/IGF2R Dom3/9mut cells exhibited
nearly the same invasiveness as mock-transfected SCC-VII cells
(7% reduction). These data suggest that a functional M6P-
binding site within domain 3 is fully sufficient to mediate the
anti-invasive properties of the receptor, whereas the M6P-binding
site in domain 9 is less effective. Inactivation of both
binding sites abolishes the anti-invasive activity of M6P/IGF2R,
which suggests that M6P-modified ligands of the receptor play
a key role in the migration of SCCs cells across basement
membranes (Figure 3).
The M6P-binding site in domain 3 is of key importance for the
growth-suppressive activities of M6P/IGF2R in SCC-VII cells
We have reported previously that expression of wt M6P/IGF2R
leads to reduced cell densities in late-stage SCC-VII cultures
[25]. To determine the impact of mutant forms of M6P/IGF2R
on SCC-VII growth, we followed the cell numbers of the
respective cultures over a period of 3 days. During the first
48 h, there were no striking differences between the growth
rates of the investigated cell lines. After 72 h of incubation,
cultures of SCC-VII cells expressing M6P/IGF2R Dom9mut were
found to contain substantially fewer cells than the controls.
This phenotype was far less pronounced upon expression of
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Figure 3 Invasive properties of SCC-VII cells expressing mutant forms of M6P/IGF2R
Matrigel invasion assays of SCC-VII cells expressing either wt or mutant M6P/IGF2R were performed using conditioned medium of fibroblasts as a chemoattractant. Mock-transfected cells
were analysed in parallel. Parental SCC-VII cells were used as controls (set to 100 %). Results are means +− S.E.M. for at least three independent experiments. *P < 0.05, compared with the
mock-transfected cells.
the other M6P-binding site mutants, indicating that M6P/IGF2R-
mediated growth arrest depends strongly on the M6P-binding site
in domain 3. Interestingly, M6P/IGF2R Dom11mut was similarly
ineffective in suppressing the growth of late-stage SCC-VII
cultures, suggesting that this activity of the receptor also requires
a functional binding site for IGF-II (Figure 4 and Supplementary
Table S3 at http://www.biochemj.org/bj/451/bj4510091add.htm).
Previous studies have revealed that SCC-VII cells are
capable of growing in an anchorage-independent manner
when cultured in a semi-solid medium. Although the
M6P/IGF2R status did not affect the efficiency of colony
formation, colonies formed by SCC-VII cells expressing wt
M6P/IGF2R were found to be significantly smaller than
those of mock-transfected and parental cells [25]. The same
observations were now made for M6P/IGF2R Dom11mut-
expressing cells, demonstrating that interaction with IGF-II is
not required for M6P/IGF2R-mediated restriction of anchorage-
independent growth. Interestingly, the median size of colonies
formed by M6P/IGF2R Dom3mut and Dom3/9mut transfectants
was close to that of parental and mock-transfected cells,
whereas colonies of M6P/IGF2R Dom9mut-producing cells were
only slightly larger than those of SCC-VII cells expressing the wt
receptor (Figure 5 and Supplementary Table S4 at http://www.
biochemj.org/bj/451/bj4510091add.htm). Taken together, these
results indicate that a functional M6P-binding site in domain 3 is
important for the capacity of M6P/IGF2R to decrease anchorage-
independent growth of SCC-VII cells, thus providing further
evidence for the pivotal importance of this binding site for the
cellular activities of the receptor.
DISCUSSION
It is currently believed that the functions of M6P/IGF2R
in development and cancer suppression rely mainly on its
ability to control the biological activities of IGF-II. Indeed,
substantial evidence has been provided that the receptor down-
regulates the growth-promoting and anti-apoptotic effects of this
potent mitogen, thus preventing developmental abnormalities
and tumour formation [10,39]. Recent studies [25–27] have
highlighted that M6P/IGF2R also has the capacity to reduce
cellular motility and invasiveness. Whereas it has been originally
suggested that this is related to altered IGF-II uptake and
degradation [40], the anti-invasive activity of the receptor has also
been recently linked to its interactions with various proteinases
[25,26]. To study the cellular impact of the interactions between
M6P/IGF2R and its diverse ligands separately, we have now
introduced inactivating mutations into the respective ligand-
binding sites prior to stable expression of these mutant receptor
cDNAs in M6P/IGF2R-deficient SCC-VII cells, which respond to
reconstitution of wt M6P/IGF2R expression with compromized
growth and invasiveness [25].
To assess the biological activities of M6P/IGF2R independent
of its interaction with IGF-II, we have generated a receptor
variant containing a point mutation within the IGF-II-binding
site (M6P/IGF2R Dom11mut). M6P/IGF2R Dom11mut was found
to be less growth-inhibitory than the wt receptor under standard
culture conditions, in line with studies performed on LNCaP
and PC-3 human prostate cancer cells [41]. However, this
M6P/IGF2R mutant is still capable of restricting anchorage-
independent growth of SCC-VII cells. Moreover, M6P/IGF2R
Dom11mut improves the intracellular accumulation of lysosomal
enzymes as efficiently as the wt receptor, thereby quantitatively
restoring the formation of dense lysosomes. Matrigel invasion
assays revealed that M6P/IGF2R Dom11mut was essentially as
anti-invasive as the wt protein. Thus it can be concluded that a
functional binding site for IGF-II is not required for the anti-
invasive activity of M6P/IGF2R in SCC-VII cells.
The impact of the M6P-binding activity of M6P/IGF2R on
cellular growth, motility and invasiveness has not yet been
directly studied. However, some cancer-associated M6P/IGF2R
mutations have been found to reduce M6P binding [18,19].
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Figure 4 In vitro growth of SCC-VII cells transfected with mutant M6P/IGF2R cDNAs
SCC-VII cells expressing either wt or mutant M6P/IGF2R were grown for 72 h under standard culture conditions prior to harvesting and cell number determination. Mock-transfected cells were analysed
in parallel. Parental SCC-VII cells were used as controls (set to 100 %). Results are means +− S.E.M. for at least three independent experiments. *P < 0.05, compared with the mock-transfected cells.
Figure 5 Anchorage-independent growth of SCC-VII cells transfected with mutant M6P/IGF2R cDNAs
SCC-VII cells expressing either wt or mutant M6P/IGF2R were cultured for 3 weeks in semi-solid medium before the median diameter of the colonies formed was determined. Mock-transfected
cells were analysed in parallel. Parental SCC-VII cells were used as controls (set to 100 %). Results are means +− S.E.M. for at least three independent experiments. *P < 0.05, compared with the
mock-transfected cells.
To determine whether missense mutations in the two M6P-
binding domains affect the growth-inhibitory and anti-invasive
activity of M6P/IGF2R, we have produced receptor variants
with inactivating point mutations within either of these binding
sites. Ligand-binding studies revealed that either of the single-
mutant receptors is still able to bind M6P, whereas the double-
mutant receptor has lost this capacity. Although it has been
reported that the two M6P-binding sites of M6P/IGF2R can
differ in their efficiencies of delivering individual acid hydrolases
to lysosomes [42], the single mutants proved almost equally
effective in mediating the intracellular accumulation of HEX
by SCC-VII cells. The same observation was made for CD, but
M6P/IGF2R Dom3mut was found to be better than M6P/IGF2R
Dom9mut in promoting the retention of CL. Secretion–recapture
pathway studies demonstrated that either single mutant matches
wt M6P/IGF2R in its capacity to act in the endocytic pathway.
However, subcellular fractionation experiments revealed that
M6P/IGF2R Dom3mut is far less effective in promoting dense
lysosome formation than M6P/IGF2R Dom9mut and the wt
receptor. This is possibly explained by the observation that some
lysosomal enzymes bind much tighter to domain 3 than to domain
9 [6].
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The double mutant M6P/IGF2R Dom3/9mut showed weak
residual activity in delivering HEX to lysosomes. This could be
owing to the presence of an additional carbohydrate-binding site
in domain 5 of the receptor, which exhibits a distinct preference
for the biosynthetic intermediate M6P-N-acetylglucosamine [6].
It has been reported that domain 5 is capable of mediating the
endocytic uptake of a variant of recombinant acid α-glucosidase
enriched in such M6P diesters [43]. However, inactivation of both
M6P-binding sites almost completely abolished the capacity of the
receptor to perform reuptake of HEX secreted by SCC-VII cells.
This is probably accounted for by the high efficiency of these
cells in uncovering phosphorylated N-glycans [31]. Furthermore,
M6P/IGF2R Dom3/9mut was found to be unable to support the
generation of dense lysosomes in SCC-VII cells, suggesting
that the carbohydrate-binding site in domain 5 is also of minor
importance for this activity of the receptor.
We have previously reported that expression of wt M6P/IGF2R
impedes the growth of SCC-VII cells both in vitro and in vivo
[25]. Analysis of SCC-VII cells expressing mutant receptors now
revealed that the M6P-binding site within domain 3 is more
important for this activity than the one in domain 9. M6P/IGF2R-
mediated growth suppression was almost completely abolished
by inactivation of both domains, thus indicating that one or
more M6P-modified protein(s) are, when secreted, capable of
promoting SCC-VII growth. One candidate for this would be the
precursor of the lysosomal aspartic proteinase CD, which has
been recently shown to act as a paracrine communicator between
cancer and stromal cells in a manner independent of its proteolytic
activity [44,45].
The anti-invasive potential of M6P/IGF2R forms lacking
individual M6P-binding sites was assessed by Matrigel invasion
assays. Although M6P/IGF2R Dom9mut displayed essentially the
same anti-invasive behaviour as the wt receptor, M6P/IGF2R
Dom3mut was found to be far less effective. Importantly,
simultaneous mutation of both M6P-binding sites abrogated the
anti-invasive activity of the receptor in SCC-VII cells. These
results clearly demonstrate that certain M6P-bearing factors are
of substantial relevance for the extent of SCC-VII invasiveness.
Thus lack of functional M6P/IGF2R expression possibly favours
cancer outgrowth and metastasis largely by enhancing the release
of M6P-modified proteins such as lysosomal proteinases and/or
other acid hydrolases into the extracellular space. This notion
is corroborated by our previous observation that the lysosomal
cysteine proteinase cathepsin B contributes to the invasive
properties of SCC-VII cells [30]. Previous studies in transgenic
mice have provided compelling evidence for multiple functions
of cysteine cathepsins such as cathepsin B and CL in tumour
invasion and metastasis [22,46,47]. However, the impact of the
M6P/IGF2R status on the extracellular accumulation of CL in
SCC-VII cultures is only moderate. Hence the pro-invasive M6P-
bearing protein(s) secreted by SCC-VII cells still remain to be
identified.
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The mannose 6-phosphate-binding sites of M6P/IGF2R determine its
capacity to suppress matrix invasion by squamous cell carcinoma cells
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Figure S1 Subcellular localization of mutant forms of M6P/IGF2R
SCC-VII cells stably expressing wt or mutant receptor variants were stained with antibodies against M6P/IGF2R and the Golgi marker GM130. The bound antibodies were then detected with FITC-
and Cy3 (indocarbocyanine)-labelled secondary antibodies by confocal laser-scanning microscopy. Colocalization was assessed by merging of the individual images. Scale bar, 10 μm.
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Table S1 M6P/IGF2R levels of SCC-VII cells expressing human receptor
variants
Results are means +− S.E.M. for at least three determinations. The M6P/IGF2R content of parental
and mock-transfected SCC-VII cells is below the detection limit of the assay (0.1 pmol/mg).
Cell line M6P/IGF2R content (pmol/mg)
SCC-VII/IGF2R wt-1* 2.1 +− 0.1
SCC-VII/IGF2R wt-2* 4.1 +− 0.1
SCC-VII/IGF2R wt-3 1.0 +− 0.1
SCC-VII/IGF2R Dom3mut-1 1.7 +− 0.3
SCC-VII/IGF2R Dom3mut-2 1.4 +− 0.2
SCC-VII/IGF2R Dom9mut-1 1.1 +− 0.1
SCC-VII/IGF2R Dom9mut-2 1.4 +− 0.1
SCC-VII/IGF2R Dom3/9mut-1 1.1 +− 0.1
SCC-VII/IGF2R Dom3/9mut-2 2.2 +− 0.1
SCC-VII/IGF2R Dom3/9mut-3 1.8 +− 0.3
SCC-VII/IGF2R Dom11mut-1 1.4 +− 0.2
SCC-VII/IGF2R Dom11mut-2 1.0 +− 0.1
SCC-VII mock-transfected <0.1
SCC-VII parental <0.1
*Taken from [1].
Table S2 Secretion of HEX by parental and transfected SCC-VII cells upon
culture for 24 h in the presence or absence of 10 mM NH4Cl
Results are means +− S.E.M. for three to eight independent experiments.
Extracellular activity (% of total)
Cell line − NH4Cl + NH4Cl
SCC-VII/IGF2R wt-1† 11 +− 2* 54 +− 4
SCC-VII/IGF2R wt-2† 20 +− 6* 58 +− 8
SCC-VII/IGF2R wt-3 24 +− 2* 54 +− 3
SCC-VII/IGF2R Dom3mut-1 31 +− 3* 46 +− 2
SCC-VII/IGF2R Dom3mut-2 23 +− 1* 45 +− 5
SCC-VII/IGF2R Dom9mut-1 20 +− 2* 58 +− 1
SCC-VII/IGF2R Dom9mut-2 24 +− 1* 50 +− 2
SCC-VII/IGF2R Dom3/9mut-1 38 +− 1* 55 +− 1
SCC-VII/IGF2R Dom3/9mut-2 33 +− 5* 54 +− 3
SCC-VII/IGF2R Dom3/9mut-3 43 +− 3* 52 +− 6
SCC-VII/IGF2R Dom11mut-1 21 +− 3* 52 +− 4
SCC-VII/IGF2R Dom11mut-2 16 +− 3* 64 +− 1
SCC-VII mock-transfected† 62 +− 3 74 +− 1
SCC-VII parental† 60 +− 5 73 +− 2
*P < 0.05, compared with mock-transfected SCC-VII cells.
†Taken from [1].
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Table S3 In vitro growth of SCC-VII cells transfected with mutant
M6P/IGF2R cDNAs
Results are means +− S.E.M. for three independent experiments.
Cell line
24 h incubation
(×105 cells)
48 h incubation
(×105 cells)
72 h incubation
(×105 cells)
SCC-VII/IGF2R wt-1 17 +− 1 63 +− 1 95 +− 2*
SCC-VII/IGF2R wt-2 15 +− 1 44 +− 1 92 +− 3*
SCC-VII/IGF2R Dom3mut-1 17 +− 3 62 +− 3 125 +− 1*
SCC-VII/IGF2R Dom3mut-2 13 +− 1 54 +− 1 144 +− 1
SCC-VII/IGF2R Dom9mut-1 19 +− 1 56 +− 1 107 +− 5*
SCC-VII/IGF2R Dom3/9mut-1 19 +− 1 58 +− 1 133 +− 2
SCC-VII/IGF2R Dom3/9mut-2 19 +− 1 62 +− 2 137 +− 1
SCC-VII/IGF2R Dom3/9mut-3 20 +− 1 63 +− 1 129 +− 2*
SCC-VII/IGF2R Dom11mut-1 15 +− 2 57 +− 5 133 +− 11
SCC-VII/IGF2R Dom11mut-2 17 +− 5 58 +− 5 148 +− 16
SCC-VII mock-transfected 19 +− 1 55 +− 1 147 +− 5
SCC-VII parental 18 +− 1 69 +− 1 159 +− 1
*P < 0.05, compared with mock-transfected SCC-VII cells.
Table S4 Anchorage-independent growth of SCC-VII cells transfected with
mutant M6P/IGF2R cDNAs
Results are means +− S.E.M. for three independent experiments.
Colony formation Colony diameter
Cell line efficiency (%) Median (mm) Range (mm)
SCC-VII/IGF2R wt-1† 9 +− 4 0.07 +− 0.03* 0.02–0.25
SCC-VII/IGF2R Dom3mut-1 6 +− 4 0.16 +− 0.08 0.02–0.61
SCC-VII/IGF2R Dom3mut-2 9 +− 4 0.19 +− 0.06 0.02–0.59
SCC-VII/IGF2R Dom9mut-1 8 +− 1 0.11 +− 0.04* 0.02–0.32
SCC-VII/IGF2R Dom3/9mut-1 7 +− 5 0.22 +− 0.06 0.02–0.62
SCC-VII/IGF2R Dom3/9mut-2 14 +− 3 0.19 +− 0.03 0.02–0.64
SCC-VII/IGF2R Dom3/9mut-3 20 +− 4 0.18 +− 0.05 0.02–0.60
SCC-VII/IGF2R Dom11mut-1 15 +− 1 0.08 +− 0.02* 0.02–0.18
SCC-VII mock-transfected† 11 +− 5 0.17 +− 0.03 0.02–0.65
SCC-VII parental† 11 +− 5 0.18 +− 0.04 0.02–0.53
*P < 0.05, compared with mock-transfected SCC-VII cells.
†Taken from [1].
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